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“The important thing is to  
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Cell proliferation requires the accurate replication of DNA and equal segregation of replicated 
genes, important for maintaining the integrity of newly formed cells. At the centre of this 
process is a series of coordinated events termed ‘the cell cycle’, which ensures cell proliferation 
proceeds with high fidelity. Cell cycle regulation is driven by the activity of cyclin-dependent 
kinases (Cdks), which require binding to their regulatory subunit cyclin to become activated. 
However, the activity of Cdk is regulated by several different mechanisms. Transcription and 
degradation control mechanisms indirectly affect Cdk activity by modulating the expression of 
several regulatory proteins, including cyclins, while regulatory phosphorylation and 
dephosphorylation of cyclin-Cdk complexes provide direct control of Cdk activity. Such post-
translational modifications are frequently part of feedback loops, which fine-tune Cdk activity. 
These mechanisms collectively modulate successive activation of Cdks, and is responsible for 
timely phosphorylation of Cdk substrates to complete different phases of the cell cycle. This 
thesis concerns the regulation of G2 phase in the cell cycle, in relation to: 1) the effect of cyclin 
A2 localisation in G2 phase, 2) the changes in G2 phase regulation in a genetic disorder, and 
3) the long-term consequences if G2 phase regulators are completely suppressed. 
Although Cdk activity is required for well-delineated cell cycle phase transitions, the spatio-
temporal regulation of cyclin is important, as it provides unique substrate specificity and 
accessibility to the Cdk. Nevertheless, the exact mechanisms underlying the activation of 
cyclin-Cdk complexes remain largely elusive. The first part of this thesis investigates unknown 
mechanisms of mitotic kinase activation in G2 phase, by assessing the spatio-temporal 
regulation of cyclin A2 and its function in G2 phase.  
In paper I, we observe that nuclear cyclin A2 partially translocates to the cytoplasm at S/G2 
phase transition. Interestingly, we reveal that cyclin A2-Cdk2 can initiate the activation of Plk1 
through phosphorylation of Bora, but only cyclin A2 localised to the cytoplasm can interact 
with Bora and Plk1. We find no evidence that the change in localisation of cyclin A2 is involved 
in feedback loops in G2 phase. Thus, our study strongly supports the notion that cytoplasmic 
A2 functions as a trigger for the activation of mitotic kinases. Although the precise mechanism 
that changes the localisation of cyclin A2 to the cytoplasm requires further study, we show that 
cyclin A2 nuclear localisation until S/G2 phase transition is contributed, in part, by the 
association of cyclin A2 to chromatin during DNA replication. In addition, our work also 
reveals p21 can restrict cyclin A2 to the nucleus, especially after DNA damage. Together, 
paper I expands our understanding of the mechanisms of mitotic kinase activation in G2 phase, 
and identifies future areas of study to fill in our knowledge gaps of how cyclin A2 changes its 
cellular localisation.  
Cell cycle dysregulation has been implicated in many genetic diseases and disorders. This 
highlights the importance of understanding cell cycle regulation in certain disease settings. The 
second part of this thesis is dedicated to studying the role of a non-coding nuclear RNA gene, 
RMRP, that is mutated in the rare genetic disorder, cartilage-hair hypoplasia (CHH). CHH cells 
show proliferation defects, and studies on yeast suggest that RMRP could regulate the 
accumulation of cyclins.  In paper II, we reveal RMRP has pleiotropic effects on several cell 
cycle regulatory genes, and the mutation of RMRP delays G2 phase progression to mitosis. 
Furthermore, our work finds evidence of possible impairment in the PI3K-Akt signalling 
pathway in CHH. These findings contribute to understanding the role of RMRP in cell cycle 
regulation, particularly in relation to CHH, and indicate a possible pathway for therapeutic 
interventions.  
The uncontrolled proliferation of cells with genomic instability can lead to the development of 
cancer. The cell cycle checkpoint is a mechanism that can restrict cell cycle progression in 
response to DNA damage and replication blocks. When checkpoint kinases are activated, 
signals are transmitted to a network of regulatory proteins that increase the inhibitory force and 
delay cell cycle progression. In the case of persistent DNA damage in G2 phase, p53 and p21-
dependent premature activation of APC/CCdh1 mediates cell cycle termination by degrading all 
cell cycle regulatory proteins. While all these processes ensure genomic integrity, the 
mechanisms that allow escape from a checkpoint have been the focus of many studies, but 
whether cell cycle termination in G2 phase can be reversed remains unclear. Therefore, the last 
part of this thesis investigates the long-term consequences of DNA damage-induced cell cycle 
termination in G2 phase.  
Paper III shows that cells can re-initiate S phase after terminating the cell cycle in G2 phase. 
Interestingly, expression of p21 persists until cells re-initiate DNA replication and increases 
further once DNA re-replication is complete. This finding supports our observation of repeated 
cell cycle termination of re-replicated cells. Furthermore, re-replicated cells can progress to 
mitosis, which creates a heterogenous cell population, and is linked to genomic instability.  
Thus, resumption of the cell cycle a long period after termination in G2 phase can give rise to 
 
 
multiple cell fates. This shifts our current perception of the long-term consequences of cell 
cycle termination in G2 phase, from a singular outcome of senescence to that of multiple cell 
fates, possibly alluding to a mechanism by which cells can undergo oncogenic transformation.  
In summary, this thesis highlights the importance of the spatio-temporal regulation of cyclin 
A2 in modulating Cdk to initiate the mitotic entry network in G2 phase, ensuring well-
delineated progression to mitosis. Identifying the function of RPRM in G2 phase adds to our 
limited understanding of cell cycle regulation in relation to CHH. Moreover, this thesis reveals 
that DNA damage-induced cell cycle termination in G2 phase can lead to cell fates other than 
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1 INTRODUCTION 
 
Cell proliferation is fundamental in all organisms, allowing a renewal of living cells. The 
accurate duplication and segregation of chromosomes are important events in the proliferation 
of cells. However, these two events constitute only the basic functions of the cell cycle. In 
1953, Alma Howard and Stephen Pelc identified the existence of two periods, G1 and G2 
phase, in addition to DNA synthesis (S phase) and cell division (mitosis), and proposed that 
proliferating cells follow successive temporal progression of these phases1: G1 phase starts 
after mitosis is completed and G2 phase begins once S phase is accomplished. This concept of 
the cell cycle assisted later identification of cell cycle time parameters and the multiple 
biochemical and molecular events that occur at each cell cycle phase. These discoveries 
highlight that the cell cycle is a complex, yet highly regulated, series of events which control 
cell proliferation.  
With advancements in molecular biology techniques, cell cycle regulation has been extensively 
researched over the past few decades, but the regulation of G2 phase remains largely elusive. 
Nevertheless, the processes involved in G2 phase reinforce cell cycle progression, but critically 
are also able to restrict the cell cycle when cell integrity is severely compromised2,3.  This 
restriction of the cell cycle can lead to cell cycle termination, which often develops into 
senescence - a state of permanent cell cycle arrest4. However, our understanding of cell fate 
decisions after cell cycle termination is open to question. Dysregulation of the mechanisms that 
enforce anti-proliferative cell fates can impose genetic instability, a pre-requisite for the 
development of cancer5,6. Interestingly, cell proliferation and its relevance to disease, has been 
hinted at as early as the initial observations by Robert Remak in 1852, who stated that cells 
arise from existing cells both in diseased and healthy tissues7. Cell proliferation is critical for 
the maintenance, development and growth of the human body8, and an accurate and orderly 
cell cycle lies at the hub of these processes. This highlights that understanding cell cycle 
regulation is key to uncovering the secrets of human disease and may provide useful targets for 
future therapeutic interventions.  
Thus, the work presented in this thesis explores how the cell cycle is regulated in normal and 
disease settings, as well as, the long-term effect on cells after DNA damage, with particular 
emphasis on G2 phase. 
 
 2 
1.1 Cell cycle engine: Cyclin and cyclin-dependent kinase complexes 
Progression through the cell cycle is primarily controlled by the activity of cyclin-dependent 
kinases (Cdks). Cdks are a family of conserved serine/threonine kinases that contain a catalytic 
core comprised of an ATP-binding pocket, PSTAIRE-like cyclin-binding domain and 
activating T-loop motif9. Activation of Cdk requires heterodimeric complex formation with its 
specific regulatory subunit cyclin and phosphorylation of threonine (Thr160) residue in the T-
loop by Cdk-activating kinase (Cak)10–12. This cell cycle machinery operates the same way in 
widely disparate organisms from yeast to higher eukaryotes.  
Although the cell cycle control mechanism is conserved, not all eukaryotes depend on the same 
types of Cdks. In yeast, a single PSTAIRE kinase (Cdc28 in S. cerevisiae and Cdc2 in S. pombe 
- homologues of Cdk1), regulates all cell cycle phases by associating with multiple phase-
specific cyclins13. In contrast, mammalian cells have evolved to have small groups of Cdks, 
with specific members sequentially activated during the cell cycle to carry out distinct 
functions14,15. Cdk4/6 controls G1 phase, Cdk2 regulates entry into S phase, and Cdk1 activity 
drives through G2 phase to initiate mitotic entry16. However, in mice, mutation of Cdk2, Cdk4 
or Cdk6 does not affect viability without major defects in the cell cycle, indicating functional 
redundancies between the different Cdks17–19. Also, while deletion of Cdk1 in Cdk2 mutant 
chicken DT40 cells prevents the initiation of DNA replication and centrosome duplication, the 
presence of a single Cdk2 allele renders S phase progression independent of Cdk1, suggesting 
that Cdk1 and Cdk2 share a function in S phase control20. Therefore, these findings challenge 
the specific function of Cdks at each assigned phase of the cell cycle. Interestingly, knocking 
out Cdk1 in mice leads to embryonic lethality during the early stages of development, and the 
functionality of Cdk1 cannot be rescued by other Cdks21. However, mice embryos lacking 
Cdk2, Cdk3, Cdk4 and Cdk6 can undergo embryonic development, and fibroblasts derived 
from these mice can proliferate in vitro22. Thus, Cdk1 seems essential in controlling the 
mammalian cell cycle, which is reminiscent of that in yeast where a single Cdk regulates the 
entire cell cycle.  
The human genome encodes at least 20 proteins that can be considered members of the Cdk 
family, based on sequence similarities in the conserved domain and an ability to be activated 
by cyclins23. The families of Cdk8, Cdk9, Cdk11 and Cdk20 have been identified to show 
activities of transcription-related regulation 24,25, but some of these Cdks are also able to directly 
regulate cell cycle progression. For example, Cdk10 (a subfamily of Cdk11) is thought to be 
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implicated in regulating the cell cycle through inhibitory regulation of Cdk1. Indeed, 
overexpression of antisense and dominant-negative mutants of Cdk10 in U2OS cells leads to 
proliferation inhibition and the dominant-negative mutants halt cell cycle progression in G2/M 
phase26. Also, Cdk10 can restrain Ets2 transcription factor, which binds to the promoter of 
Cdk1 through its kinase activity, either by complexing with cyclin M to promote ubiquitin 
ligase/mediated Ets2 degradation27,28, or by its direct association with the N-terminal pointed 
domain of Ets2 to inhibit transactivation of Ets229. Similar to Cdk10, which regulates the cell 
cycle independent of cyclin, canonical or transcriptional cyclins have also been shown to carry 
out cellular functions that do not require interaction with a Cdk. Independent of Cdk4, cyclin 
D1 overexpression transcriptionally activates oestrogen receptors in murine derived SCp2 
cells30. An oestrogen receptor-positive status correlates with cyclin D1 overexpression in 
human breast cancer31–33, therefore cyclin D1 may exert an oncogenic potential in breast cancer. 
Also, cyclin A2 can directly bind to Mre11 transcripts, independent of Cdk, to facilitate 
polysome loading and translation, which ensures adequate repair of common replication 
errors34. In S. cerevisiae, cyclin C translocates to the cytoplasm in response to oxidative stress 
and directly interacts with Mdv1p, an adaptor protein that is required for mitochondrial 
fission35. Together, these findings suggest that although canonical cyclin-Cdk complexes are 
undoubtedly core cell cycle engines in cell cycle regulation, the functions and substrates of 
many cyclins and Cdks remain unknown. Thus, explaining the cell cycle based on canonical 
cyclin-Cdk complexes is an over simplification.  
In summary, the cell cycle truly works like a clock, with canonical cyclin-Cdk complexes 
representing the cell cycle’s movement, while several hidden internal molecular components 
tightly regulate this movement. While cell cycle functions and mechanisms have been 
discovered using models across species, including yeast, amphibians and Drosophila, the work 
presented in this thesis focuses on human cell cycle regulation. Therefore, the human 







1.2 Cyclin-Cdk activity and substrate specificity 
While the concentrations of Cdks remain relatively constant throughout the cell cycle, different 
cyclins are expressed according to the cell cycle phases16. This reflects the oscillatory 
expression of specific cyclin-Cdk complexes at different cell cycle stages, which serve as 
molecular switches that regulate cell cycle transitions36. In human cells, cyclin D-Cdk4/6 is 
active in G1 phase, cyclin E-Cdk2 at the G1/S border, cyclin A2-Cdk2 during S phase, cyclin 
A2-Cdk1 at S/G2 border, and cyclin B1-Cdk1 during G2/M phase transition37–40. The timely 
phosphorylation of target proteins by cyclin-Cdk complexes are essential in cell cycle 
transition41–49, and how the different cyclins drive distinct phases of the cell cycle has been 
previously debated. Since cyclins modulate Cdk substrate specificity or change Cdk subcellular 
localisations50,51, a model has been proposed where the intrinsic functional capacities of cyclins 
drive cell cycle transition. This ‘qualitative model’ of cyclin function is supported by several 
findings from the biochemical characterisation of yeast and metazoan cyclin-Cdk 
complexes47,52–56. In S. cerevisiae, cyclins exhibit substrate site-specificity and have the ability 
to compensate, by a docking interaction, for a gradual decrease in the specificity of early cyclin-
Cdk1 complexes54. Similarly, it has been shown in mammalian cells that cyclin D-Cdk4/6 
targets Rb for phosphorylation through recognition of the C-terminal alpha-helix on Rb, the 
mutation of which leads to arrest in G1 phase. Also, the C-terminal alpha-helix is not 
recognised by cyclin E-Cdk2, cyclin A-Cdk2, and cyclin B-Cdk1 complexes, suggesting Cdk 
specificity is determined by intrinsic selectivity of the active site and by the substrate docking 
site on the cyclin subunit57 
However, for the qualitative model to work, specific cyclin-Cdks have to be available during 
the assigned phase in order to transition through the cell cycle without major impact. The 
observation of mitotic cyclin in S. pombe, promoting both S phase and mitosis in the absence 
of G1 phase cyclins58, suggests that the substrate specificity of different cyclin-Cdk complexes 
may be less important for regulating orderly cell cycle transition. This apparent plasticity is 
also reported in other eukaryotes. As discussed, genetic elimination of specific cyclins-Cdks 
do not have a major impact on the cell cycle order in in vivo and in vitro murine systems22,59–61. 
Since the multiple specific docking interactions on Rb are recognised by cyclin D57, and in the 
absence of Cdk4/6, the non-consensus interaction between cyclin D and Cdk2 can form and 
play compensatory roles18,62. Thus, the formation of non-canonical cyclin-Cdk complexes 
could, at least partly, reconcile a qualitative model with the lack of phenotype after depletion 
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of individual Cdks. In Xenopus oocytes, cyclin B1 nuclear translocation induces a gradual 
increase in Cdk1 activity that first initiates replication and subsequently induces mitotic entry. 
This suggests Cdk subcellular localisation controls Cdk activity and therefore is a critical factor 
in determining Cdk specificity63. These findings support a model which proposes quantitative 
changes in the levels of Cdk activity regulate progression of the cell cycle in an orderly 
manner64.  
In this ‘quantitative model’, the functional differences between cyclins are primarily explained 
by differences in their expression levels and timings. It has been shown that Cdh1 ablation 
lessens the strength of the double-negative feedback loop generated between Cdk2 and Cdk 
inhibitor, p27, resulting in a more linear response of Cdk2 to cyclin E, with premature entry 
into S phase, while delaying S phase progression. This demonstrates that a timely increase of 
Cdk2 activity to its threshold is required for scheduled S phase transition and progression65,66. 
In line with this, expression of constitutively active Cdk1 in human somatic cells shortens the 
duration of G1 and S phases, allowing progression into a mitotic-like state without proper 
completion of S or G2 phases, indicating that low Cdk1 activity is required for S phase 
progression67. During S phase, cyclin A2-Cdk2 activity increases as cyclin A2 synthesis 
increases, which is shown to promote disassembly of the origin recognition complex, thereby 
helping to restrict origin firing to only once per S phase68,69. However, an increase of Cdk 
activity above a certain threshold induces premature phosphorylation of mitotic targets, which 
suggests that keeping Cdk2 activity at an intermediate level is required to maintain S phase70–
72. At the end of S phase, cyclin A2 and B1 transcription starts to increase rapidly, which 
increases Cdk1 activity to a threshold where it phosphorylates multiple substrates involved in 
the onset of mitosis73,74. Taken together, these findings support a quantitative model of cyclin 
function, where gradually increasing cyclin-Cdk activity sequentially induces cell cycle events.  
While the biochemical characterisation of cyclin-Cdk complexes highlights the qualitative 
model of cyclin function47,52–56, the phosphoproteomic-based study of S. pombe implicates both 
the qualitative and quantitative models of cyclin function in controlling the cell cycle75. The 
monotonic rise in activity of cyclin-Cdk complexes induces timely phosphorylation of its 
substrates, by proceeding through sequential substrate-specific activity thresholds and in part 
by the affinity of substrates towards the cyclin-Cdk complexes75. Furthermore, although genetic 
elimination studies demonstrate the redundancy of Cdk2, Cdk4 and Cdk622,59–61, a chemical-
genetic based study reveals that Cdk2 is required for G1/S phase transition when normal cyclin 
pairing is maintained76,77. Together these studies indicate that cell cycle progression is guided 
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by Cdk activity thresholds, while cyclin-generated specificity contributes to fine tuning of this 
activity.  
1.3 Operations of the cell cycle engine 
1.3.1 Temporal regulation: Cyclin synthesis and degradation 
Physical association with cyclins is essential for Cdk activation, and the synthesis and 
degradation of cyclins are regulated throughout the cell cycle.  Unbound cyclin D is relatively 
unstable and its expression levels are adjusted with some precision depending on the presence 
of extracellular mitogen signals and signalling cascades. Transcription of cyclin D is promoted 
by several transcription factors, including c-Jun, c-Fos, ATF2, Ets2, SP1, TCFs and Myc, 
which convey mitogenic signalling cues78–82. In contrast, cyclin E, A and B expressions are 
mostly independent of extracellular mitogenic signalling and regulated at transcriptional or 
post-transcriptional levels83–85. The Rb/E2F transcriptional pathway is most characterised in the 
G1/S phase transition. In the prevailing model, gradual phosphorylation of Rb by cyclin D-
Cdk4/6 releases E2F for transcriptional upregulation of cyclin E, which in turn promotes its 
own transcription through a positive feedback loop86,87. However,  a recent study has shown 
that Rb is only exclusively monophosphorylated by cyclin D-Cdk4/6 in G1 phase, and E2F 
transcriptional activation is driven by cyclin E-Cdk2-dependent hyper-phosphorylation of Rb 
at the G1/S phase restriction point88. Thus, how cyclin E is activated remains unclear. However, 
Myc is reported to increase cyclin E gene expression89, indicating that Cdk activity-dependent 
transcriptional control of G1/S phase transition could be regulated by a different transcriptional 
pathway.  
Together with transcription, two ubiquitin E3 ligase complexes, SCF and APC/C, play a role 
in guarding against inappropriate or untimely accumulation of cyclins throughout the cell 
cycle90. In late G1 phase, cyclin E-Cdk2 dependent phosphorylation of Cdk inhibitor p27 at 
Thr187 residue91–93 is recognised by F-box protein Skp2, which functions as the receptor 
component of the SCF ubiquitin ligase complex94–96. This recognition consequently promotes 
ubiquitin-dependent degradation of p27, which prevents inhibition of cyclin A in S phase.  
Skp2 also targets free cyclin E, which is unbound from Cdk2, for ubiquitylation97. As S phase 
progresses, Cdk2-mediated phosphorylation promotes SCFFbw7-mediated ubiquitination and 
degradation of cyclin E83,98, while E2F-regulated transcription of cyclin A increases99,100. Also, 
factors affecting cyclin transcription are modified post-translationally, including being targeted 
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for ubiquitin-mediated degradation. At the beginning of S phase, cyclin A2-Cdk 
phosphorylates activator E2Fs, thereby preventing its ability to bind DNA and mediate 
transactivation 42,101,102. In early G2 phase, cyclin A2-Cdk-dependent phosphorylation of  B-
Myb and FoxM1 promotes cyclin B1 transcription103,104. Cyclin F, the founding member of the 
F-box protein family of the SCF substrate receptor, targets activator E2Fs for proteosomal 
degradation on entry to G2 phase105,106. Also SCFCyclin F is implicated in regulating G2/M phase 
transition by promoting degradation of atypical repressor E2Fs in G2 phase to ensure the 
expression of DNA repair genes107. 
Increasing Cdk activity phosphorylates Cdh1 to inhibit its binding to APC/C, which allows 
accumulation of cyclin A and cyclin B throughout S to G2 phase108.  SCF may play a role in 
promoting cyclin A and cyclin B accumulation by promoting the degradation of Cdh1. Cyclin 
F is also shown to contribute to APC/C inactivation through promoting Cdh1 degradation, 
providing additional regulation to the G1/S phase transition109. In early mitosis, Cdk1-
dependent phosphorylation of APC/C increases its binding affinity for Cdc20, mediating 
degradation of cyclin A at prometaphase, whereas Cdh1 dephosphorylation in anaphase 
activates APC/CCdh1 for cyclin B degradation110. Although APC/C inactivation by the spindle 
assembly checkpoint (SAC) delays degradation of cyclin B until completion of microtubule 
attachment to the kinetochores111, cyclin A degradation is permitted by an active SAC112. The 
temporal and sensitivity differences in these two mitotic cyclins depend, at least in part, on 
Cks1-mediated recruitment of cyclin A-Cdk1 to the phosphorylated APC/C subunit112. 
APC/CCdh1 remains active during G1 phase, which promotes cyclin B degradation113, as well as, 
preventing unscheduled accumulation of cyclin A, thereby maintaining the expression of pro-
mitotic regulators at a low level114.  
As discussed, several positive and negative feedback loops are present within the network that 
controls cyclin expression111,115, making these feedback mechanisms more important than 





1.4 Regulation of Cdk activity: Post-translational modifications 
The activation of Cdk requires more than just the binding of cyclin to Cdk73. Post-translational 
modification is another important regulatory input that regulates Cdk activity. Upon binding of 
cyclin, the Cdk conformational change allows phosphorylation of the conserved threonine 
residue in the T-loop by Cdk-activating kinases (CAKs)10. At this point Cdk is activated, 
however, at low concentrations of cyclin, Wee1/Myt1 kinases restrain Cdk activity by 
phosphorylating the Thr14 and Tyr15 residues116–118. When the concentration of cyclin exceeds 
its threshold Cdc25 phosphatases antagonise Wee1/Myt1, activating Cdk by 
dephosphorylating the inhibitory phosphates from its aforementioned residues119,120. In humans, 
three isoforms of Cdc25 (Cdc25A,-B and -C) exist, each of which are responsible for 
influencing the transition between specific phases of the cell cycle121. 
 




Cdk1 can also self-promote its own activity by directly regulating Wee1/Myt1 and Cdc25. 
Active Cdk1 inhibits Wee1 by phosphorylation, which promotes SCFβ-TrCP-dependent 
degradation and consequently removes the inhibitory force that was limiting Cdk activity122–124. 
In contrast, Cdc25 is in turn stabilised and activated by Cdk1-dependent phosphorylation, 
thereby further promoting Cdk activation125. These events create double negative and positive 
feedback loops, respectively, thereby self-promoting phase transition in a robust and 
irreversible manner126. Also, Cdk-dependent phosphorylation of Wee1 and Cdc25C is highly 
ultrasensitive, generated by multisite phosphorylation over a narrow range of Cdk1 activity in 
a rapid and switch-like manner127,128. In other words, phosphorylation is inefficient at low levels 
of Cdk activity, thereby maintaining an inactive steady-state, but as Cdk levels start to rise 
phosphorylation increases abruptly in a non-linear manner, switching Cdk activity to a fully 
active steady-state. Thus, taken together the feedback mechanisms and ultrasensitivity enable 
Cdk activity to switch between two steady-states, which explains the highly non-linear and 
bistable dynamics of Cdk activation at mitotic entry129.  
Figure 1.  Activation of Cyclin-Cdk complex by phosphorylation of the T-loop 
by Cdk-activating kinase (CAK). 
 
 





                           
                    
 
          Figure 2. Activation of cyclin-Cdk by the balanced action of Wee1/Myt1 and Cdc25.  
 
In addition to direct regulation of Cdk by phosphorylation at Thr14 and Tyr15, several 
phosphatases and kinases introduce additional feedback loops that indirectly regulate Cdk 
activity130. In this context, courtesy of Cdk activation, Wee1 and Cdc25 promote Polo-like 
kinase 1 (Plk1) for phosphorylation, which subsequently activates Cdk, further increasing its 
activity131. In contrast, several phosphatases counteract the activation of Cdk by 
dephosphorylating Cdk targets. The ability of phosphatases to regulate phosphorylation status 
has been shown to be crucial for proper progression of the cell cycle132–134. The importance of 
phosphatases in cell cycle regulation is most apparent at mitosis exit, where timely 
dephosphorylation of Cdk targets by PP1 and PP2A ensures successful completion of 
mitosis135,136. Indeed, depletion of PP2A in Xenopus egg extracts has been shown to cause 
hyperphosphorylation of Cdk targets, leading to premature mitotic entry with low levels of Cdk 
activity, and a subsequent failure to exit mitosis132.  
In interphase regulation, the PP2A family of phosphatases dephosphorylate Cdc25 and Wee1, 
thus counteracting Cdk-dependent phosphorylation. At the G2/M phase transition, Cdk-
dependent activation of Greatwall kinases (Gwl) promotes phosphorylation of its substrate, 
Arpp19/Endosulfin-α. This directly inhibits PP2A, thereby preventing dephosphorylation of 
mitotic substrates during mitosis132,135,137–139. PP2A and Gwl are implicated in multi-layer 
feedback loops, which regulate Cdk activity. Cdk-dependent activation of Gwl inhibits 
dephosphorylation of Wee1 and Cdc25 by PP2A, resulting in enhanced activation of Cdk, 
while further promoting inactivation of PP2A140,141. This coherent feedforward loop contributes 
to the non-linear bistability of the mitotic entry network, which reinforces the decision to enter 




1.5 Spatial regulation 
Cyclins are essential for activating Cdk, but also provide specificity to the action of Cdks by 
influencing Cdk subcellular localisation. This change in localisation allows Cdk to access 
spatially-restricted substrates or regulators in the cell142–146, and cyclins also provide docking 
sites for certain Cdk substrates55,147. Thus, the spatio-temporal regulation of cyclin localisation 
determines the successful function of Cdk.  
Cyclins localise differently in the cell during interphase; cyclin E and A (S phase onwards) are 
predominantly localised in the nucleus99,148, whereas cyclin B mainly resides in the 
cytoplasm149. However, these cyclins are able to move between the nucleus and cytoplasm at 
specific times and are mediated by distinct shuttling mechanisms. Cyclin E contains a nuclear 
localisation sequence (NLS) at the N-terminus and its interaction with Importin-α/β drives 
translocation of cyclin E to the nucleus144.  This localisation change is essential for the ability 
of cyclin E to promote the initiation of DNA replication150.  
Similar to cyclin E, translocation of cyclin B relies on the Importin/Exportin system. The 
interaction between Exportin1/Crm1 and the cytoplasmic retention sequence (CRS), which 
contains the nuclear export sequence (NES) at the N-terminus of cyclin B, promotes the 
cytoplasmic localisation of cyclin B151. Although cyclin B is constantly shuffled between the 
cytoplasm and nucleus during interphase, the rate of constitutive nuclear import is slower than 
the export rate with the net rate reflecting the cytoplasmic localisation of cyclin B142,143,152. Auto-
phosphorylation of the CRS of cyclin B1 directs cyclin B1 for centrosome accumulation 
towards late G2 phase, which facilitates the interaction between cyclin B and other cell cycle 
regulators, including Plk1, Aurora A and Cdc25B/C, creating an active Cdk1 pool at G2/M 
phase153,154. In this sense, the centrosome provides a similar spatial function to that of the 
nucleus for cyclin B1-Cdk1 activation, and serves as a site where proteins that trigger mitosis 
can integrate155. Immediately preceding nuclear envelope breakdown (NEB), increasing Cdk1 
activity modifies the nuclear transport machinery to greatly increase the nuclear import rate, 
triggering a rapid import of cyclin B1 into the nucleus156. Nuclear cyclin B1-Cdk1 is reported 
to activate the remaining cytoplasmic cyclin B1 by phosphorylation, and as a result further 
promotes cyclin B1 influx into the nucleus157. This spatial positive feedback loop is abolished 
when phosphorylation sites (Ser116, 126, 128, 133, and 147) in the CRS of cyclin B1 are 
mutated to alanine, which also delays the timing of nuclear translocation of cyclin B1 
concomitant with the NEB157. However, these findings are in contradiction with a report where 
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phosphorylation of cyclin B1 is only required during interphase for initial activation in the 
cytoplasm, and is not necessary for rapid cyclin B1 nuclear translocation at prophase156. 
Regardless of the mechanism of nuclear translocation, the cytoplasmic retention of cyclin B1 
prevents premature mitotic entry in higher eukaryotes, suggesting that the function of cyclin-
Cdk localisation control contributes to regulating its activity63.  
Cyclin A also moves dynamically between the cytoplasm and nucleus, but mainly localises in 
the nucleus due to its steady-state concentration99. Since neither cyclin A nor its kinase partner 
contain an NLS consensus, how cyclin A is spatially controlled remains debatable. However, 
it has been shown that nuclear localisation of cyclin A correlates with its ability to form a 
complex with Cdk, suggesting cyclin A nuclear translocation may be subject to the formation 
of a multiprotein complex, which includes a Cdk catalytic subunit158.  Cyclin A can bind to a 
number of NLS-containing proteins including  p107, E2F1 and p21 45,159,160.  Furthermore, ER-
associated protein, SCAPER, has been identified to specifically interact with cyclin A in a cell 
cycle-dependent manner and its association promotes transient cytoplasmic localisation161. 
These findings suggested a mechanism whereby cyclin A binds to NLS-containing proteins to 
translocate to the nucleus162. However, it has been demonstrated that cyclin A is able to 
correctly translocate to the nucleus in p21-/- mice embryonic fibroblasts163. Thus, the idea that 
cyclin A re-localisation relies on NLS-containing proteins needs to be fully elucidated.  
Besides cyclins, other proteins also have an ability to move between the nucleus and cytoplasm. 
A family of Cdc25 phosphatases containing an NES and NLS in their sequences, serve as a 
tool for facilitating the local activation of Cdks164,165. Cdc25B has been reported to specifically 
dephosphorylate Cdk inhibitory residues to activate cyclin B1-Cdk1 on the centrosomes, and 
is implicated in the initial site-specific activation of Cdk166. In line with this, Cdc25B is also re-
localised to the cytoplasm in response to DNA damage, which creates spatial separation from 
cyclin-Cdk, and as such prevents nuclear Cdk activity167. During prophase, Plk1 phosphorylates 
the Ser198 residue in the NES of Cdc25C, promoting Cdc25C nuclear translocation where it 
inhibits Wee1168. The cytoplasmic translocation of Plk1 phosphorylates and inactivates Myt1, 
which promotes the local activation of cyclin B1-Cdk1. This creates a spatial feedback loop, 
further activating cyclin B1 and Cdc25, thereby contributing to the rapid nuclear import of 
cyclin B1-Cdk1 prior to mitotic entry155,169–172.  
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1.6 G2 phase: Preparing for mitotic entry 
1.6.1 Cyclin A2 and cyclin B1: An overview 
Both cyclin A and B are accountable for regulating progression through G2 phase to mitosis, 
but have different characteristics and distinct roles during the cell cycle39. In humans, cyclin A 
(A1 and A2) and cyclin B (B1, B2, and B3) types are expressed in somatic cells, but cyclin A1 
and B3 are mainly implicated in meiosis, while cyclin A2 and B1 mostly perform functions in 
G2/M phase173–176.   
In G2 phase, cyclin A2 facilitates transcriptional activation of kinases that are essential in G2/M 
phase progression, including cyclin B1, Cdc25 and Plk1177–179. At the G2/M phase transition, 
cyclin A2 coordinates centrosomal and nuclear events as an upstream regulator of cyclin B1-
Cdk1180,181. In this context, during G2 phase, cyclin A2 regulates activities that are involved in 
creating positive feedback loops to increase cyclin B1-Cdk1 activity182,183. At mitotic entry, 
cyclin A2-Cdk promotes cyclin B1-Cdk1 nuclear translocation, chromosome condensation and 
NEB184,185. The role of cyclin A2 extends to prometaphase, where it facilitates chromosome 
segregation186.   
The main functions of cyclin B1-Cdk1 are to initiate mitotic entry and to ensure correct 
progression through mitosis. Cyclin B1 is first detected at the beginning of G2 phase and 
abruptly increases to its maximum level at mitosis39,187,188 with support from the amplifying 
actions of several feedback loops111,115. APC/C-mediated degradation of cyclin B1 takes place 
at the metaphase/anaphase transition113. The catalytic activity of cyclin B1-Cdk1 is inhibited 
during G2 phase and this complex accumulates in the cytoplasm189,190. A small fraction of 
cytoplasmic cyclin B-Cdk1 translocates to the centrosome at the time of centrosome 
duplication191. This localisation change reflects its role in the initiation and separation of the 
centrosome, microtubule network reorganisation, and activation of several targets that regulate 
specific processes in mitosis192–194. The final, yet important role of cyclin B1-Cdk1 is to fully 
activate APC/C to promote its own subsequent degradation, as well as, degrading other 
regulators responsible for chromosome separation195. This step is required to reduce mitotic 
activities to a basal level, resetting the system so it can initiate a new cell cycle.  
Since cyclin A2-Cdk drives G2 phase progression and facilitates the build-up of cyclin B2-
Cdk1 activity to initiate mitotic entry, the regulation of G2 phase will focus on cyclin A2-Cdk 
function.  
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1.6.2 Cyclin A2-Cdk: The role of G2 phase progression and mitotic entry 
Cyclin A2 is unique in that it has biphasic activity owing to its ability to form a complex with 
both Cdk2 and Cdk1196,197. Cyclin A2-Cdk2 is initially activated at the beginning of S phase, 
while a much stronger activation occurs in early G2 phase. This precedes cyclin B1-Cdk1 
activation at G2/M phase, which makes cyclin A a regulator of G2 phase progression85. Despite 
this, the role of cyclin A-Cdk2 in G2 phase progression is relatively less well known than its 
implications in S phase. However, studies in different systems indicate a function for cyclin 
A2-Cdk2 in G2 phase progression. Induction of dominant-negative Cdk2 in human cells 
prevents G2/M phase transition198, while in Drosophila cells cyclin A induces cell cycle arrest 
in G2 phase after removal of maternal cyclin A199. In human cells, siRNA depletion of cyclin 
A2 and inhibition of Cdk2, delay G2 phase progression and decrease cyclin B1-Cdk1 
activity180. It has been shown that depletion of cyclin A and inhibition of Cdk2, in early G2 
phase, decrease Cdh1 levels by stabilising the APC/CCdh1 target, Claspin, and maintain the 
levels of activated Chk1, thereby arresting cells in G2 phase200. Furthermore, introducing cyclin 
A2-Cdk2 into early G2 phase Hela cells stimulates premature entry into mitosis181, while a loss 
of cyclin A2 in G2 phase prevents mitotic entry74. Together, these findings suggest that cyclin 
A2-Cdk2 is an important rate-limiting component required for progression of G2 phase to 
mitotic entry.  
The involvement of cyclin A in G2/M phase has been the subject of many studies, but its exact 
role and downstream targets for promoting mitotic entry have only recently started to be 
identified. Cyclin A2-Cdk2 is recognised as a major regulator of Cdc25C for antagonising 
Cdk1 Tyr15 phosphorylation180,182, and stabilising cyclin B1, by phosphorylating Cdh1 for 
inhibiting APC/CCdh1-mediated proteolysis 200,201. Meanwhile, cyclin A2-Cdk1 is initially 
activated in the middle of S phase and continues to increase until G2/M phase202.  Recent 
discoveries have demonstrated the role of cyclin A2-Cdk1 in G2/M phase transition by 
promoting Plk1 activation203–206. Since Plk1 activation involves kinases other than Cdk1, the 
regulation of Plk1 by cyclin A2-Cdk2  is discussed in the following section. Cyclin A2-Cdk1 
is degraded by the APC/C during prometaphase207, in other words, it is required until that time. 
Mitotic entry initiates at prophase with centrosomal activation of cyclin B1-Cdk1 promoting 
microtubule nucleation at the centrosome155,208. A study on Xenopus egg extracts has shown 
that cyclin A-Cdk stimulates microtubule nucleating activity in the centrosomes209. This 
indicates that cyclin A-Cdk could have a role beyond promoting mitotic entry and establishes 
mitosis through affecting the mitotic machinery. In line with this, cyclin A2-Cdk2 depletion in 
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human cells results in a premature and increased microtubule nucleation at the centrosome with  
increased cyclin B1-Cdk1 activity180. In addition, cyclin A2-Cdk2 translocates to the 
centrosome shortly after centrosome separation in late G2 phase. Thus, cyclin A2-Cdk2 
centrosomal localisation in late G2 phase coordinates nuclear and centrosomal mitotic 
events165. Furthermore, a recent study has shown that cyclin A facilitates kinetochore 
microtubule attachment and functions as a timer in prometaphase to ensure error correction and 
faithful chromosome segregation186.  
 
1.6.3 Polo-like-kinase 1 (Plk1) 
Plk1 is a serine/threonine kinase, which contains an N-terminal kinase domain (KD) and a C-
terminal domain, termed the Polo-box domain (PBD), which engages in protein interaction210. 
Plk1 is involved in regulating many different functions, including centrosome maturation, 
chromosome condensation, spindle assembly and cytokinesis211,212. In order to regulate these 
different functions, Plk1 needs to be activated in a timely manner and dynamically recruited to 
specific locations213.  Plk1 localisation is controlled by substrate interactions with the PBD, 
which enables the KD to phosphorylate various effectors214.  The PBD is a phospho-peptide 
domain and preferentially binds to phosphorylated targets prior to Plk1 docking, i.e. it requires 
priming phosphorylation215. This priming phosphorylation is usually mediated by Cdk1 during 
mitosis, however, during G2 phase when Cdk1 activity is low, Plk1 phosphorylates its targets 
before subsequent binding216. Moreover, reciprocal inhibitory action by the interaction between 
the PBD and KD keeps Plk1 in an inactive state217,218. Thus, Plk1 activation relies on post-
translational modification and structural changes210.  
 
1.6.4 Mechanism of Plk1 regulation at the G2/M phase transition 
Plk1 is activated by phosphorylation of the Thr210 residue in its T-loop. Phosphorylation at 
this residue is primarily mediated by Aurora A219,220. Aurora A is diffusely distributed 
throughout the cytoplasm until late G2 phase, and a fraction is enriched in the centrosomes and 
spindle microtubules, where it rapidly exchanges with cytoplasmic pools221,222.  It has been 
reported that the initial phosphorylation of Plk1 occurs in the centrosome during G2 phase, 
however, concomitant with its activation Plk1 quickly translocates to the nucleus in 
prophase223. Furthermore, restricting Plk1 localisation in either the nucleus or in the cytoplasm 
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prevents entry into mitosis223, which highlights the importance of nuclear import as a 
mechanism of activating Plk1.   
Plk1 phosphorylation at the Thr210 residue in the KD has been shown to disrupt binding of the 
PBD to the KD217.  This dissociation of the PBD and KD exposes the NLS in the KD, enabling 
nuclear translocation of Plk1224. Thus, Plk1 can rapidly translocate to the nucleus upon its 
activation. However, SUMOylation of the PBD at Lys492 in human cells is also shown to be 
responsible for Plk1 nuclear import.  This process is facilitated by the SUMO conjugating 
enzyme, Ubc9. Cdk1-dependent phosphorylation of Ubc9 enhances its binding to Plk1, as well 
as, increases the SUMOylation activity of Ubc9225. Nevertheless, the functional relationship 
between KD phosphorylation in activating Plk1, and PBD SUMOylation in Plk1 nuclear 
translocation, requires further exploration.   
 
1.6.5 The contribution of Plk1 in mitotic entry by creating a feedback loop 
Plk1 is an upstream regulator of Cdc25B and Cdc25C isoforms in humans226, and nuclear 
translocation of Cdc25B and Cdc25C has been observed upon Plk1 activation168,170. Plk1 
phosphorylation of Cdc25C at multiple residues in its N-terminus during mitotic entry has also 
been reported. Overexpression of phosphomimetic Cdc25C mutants progress into mitosis, even 
in the absence of Plk1 activity203, suggesting that Plk1-dependent phosphorylation of Cdc25C 
in late G2 phase is essential in promoting a timely G2/M phase transition.  Nevertheless, studies 
around how much Plk1 contributes to promoting mitotic entry by regulating Cdc25A and B are 
currently limited.  
Besides controlling Cdc25, Plk1 also supports transition into mitosis by regulating other 
kinases. Plk1-dependent phosphorylation of Wee1 paves the way for its proteasome-dependent 
degradation upon ubiquitination, thereby enhancing the Cdc25 positive feedback loop227. Plk1 
also regulates Gwl, a kinase that antagonises the dephosphorylating action of PP2A-B55 
complex to promote mitotic entry. As mitosis begins, Gwl phosphorylates Arpp19/Endosulfin-
α, which in turn selectively inhibits PP2A-B55132,135,137–139.  Gwl translocates to the cytoplasm 
in prophase, where PP2A-B55 is also concentrated, and this localisation change is important 
for Gwl function 228,229. It has been shown that the cytoplasmic translocation of Gwl just before 
NEB is facilitated by Plk1 and Cdk1-dependent phosphorylation in  Drosophila 229. However, 
Cdk1 is only responsible for the spatial regulation of Gwl in human cells228.  
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1.6.6 Plk1 upstream regulators: Cyclin A2-Cdk2/1 and cyclin B1-Cdk1  
Aurora A cofactor Bora is essential in Plk1 activation, and is conserved from  C. elegans to 
humans230. During G2 phase, Bora exclusively localises in the cytoplasm and facilitates Plk1 
phosphorylation at Thr210 on its T-loop by Aurora A at late G2 phase223. Importantly, Cdk 
activity promotes the function of Bora in Plk1 activation . It has been shown that Cdk 
phosphorylates Bora at multiple serine/threonine residues, but phosphorylation of the three 
most conserved residues in the its N-terminus are essential for the function of Bora in Plk1 
activation204. Thus, Cdk activity regulates Plk1 activity by phosphorylating its downstream 
targets to prime their interaction with the PBD, as well as, activating Plk1 via Aurora A232.   
It has been a long-standing question as to what activates Bora, and thereby Plk1, in G2 phase. 
Bora can be phosphorylated by cyclin B1-Cdk1 and cyclin A2-Cdk2/1, as it contains a cyclin 
binding motif204–206.  Since Plk1 is activated in late G2 phase, shortly before cyclin B1-Cdk1 
activation203, cyclin A2-Cdk2/1 is considered a better candidate for phosphorylating Bora. 
Indeed, recently we have reported that in human cells in vitro, cyclin A2-Cdk2 can activate 
Plk1 by phosphorylating Bora in G2 phase, and that Bora and Plk1 interacts exclusively with 
cytoplasmic cyclin A2205.  On the other hand, others have reported that cyclin A2-Cdk1 can 
activate Plk1 to promote mitotic entry by phosphorylating Bora in G2 phase203,204. A study 
conducted on Xenopus egg extracts has shown that Bora depleted interphase extracts failed to 
reactivate Plk1, dephosphorylated Cdk1 at Tyr15, and blocked entry into mitosis after adding 
recombinant hyperactive Gwl206. Interestingly, in this study, the addition of the N-terminal 
fragment (human/Xenopus) corresponding to the most conserved phosphorylation sites rescued 
mitotic entry, but only when the phosphorylation residues and cyclin binding site were 
preserved. However, endogenous Bora cannot be re-activated in the absence of cyclin A, and 
introducing Bora that is resistant to endogenous phosphatases solely into a cyclin A depleted 
extract, rescues Plk1 phosphorylation and mitotic entry, suggesting that cyclin A-Cdk1 is 
dispensable for mitotic entry once Bora is fully phosphorylated. Taken together, these findings 
demonstrate that phosphorylation of Bora by cyclin A-Cdk complex in G2 phase is essential 
and sufficient for Plk1 phosphorylation and mitotic entry206.  Taken further, another study has 
reported that cyclin B1-Cdk1 associates with Bora in mitosis204, which suggests that cyclin B1-
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1.7 Cell cycle dysregulation and its relevance in disease 
Cartilage-hair hypoplasia (CHH) is a skeletal dysplasia inherited as an autosomal recessive 
trait, arising from mutations in the non-coding RNA component of mitochondrial RNA-
processing endoribonuclease, encoded by the RNase MRP gene (RMRP)233,234. CHH is a 
pleiotropic disorder and affected individuals are characterized by impaired T-lymphocyte 
function, defects in cell proliferation and an increased susceptibility to developing cancer235. It 
was recently reported that small RNAs derived by the RMRP gene display regulatory properties 
in over 900 genes, including genes that regulate cell proliferation236. In line with this finding, 
others have reported that knockdown of RMRP significantly inhibits cell proliferation in in 
vitro and in vivo, while over expression of this gene promotes cell growth237. In addition, RMRP 
forms a complex with telomerase-associated reverse transcriptase (TERT) and regulates gene 
expression through RNA-dependent RNA polymerase activity238. This activity has been 
identified in highly malignant tumour cells. Although, telomerase activity in CHH is not 
addressed in this study, the interaction of RMRP with TERT raises the possibility that telomere 
dysfunction forms part of the cellular phenotype of this disorder. 
 
1.8 Cell cycle regulation in response to DNA damage 
1.8.1 DNA damage: Double strand breaks 
The bases of DNA are highly vulnerable to chemical modifications, which can create numerous 
lesions239. DNA lesions affect essential genomic processes, such as transcription and 
replication. A normal human cell encounters up to 105 spontaneous DNA lesions per day, of 
which 0.1% are thought to be DNA double-strand breaks (DSBs) 240–242. While DSBs do not 
occur as frequently as single-strand breaks (SSBs), DSBs are the most cytotoxic form of DNA 
lesions and difficult to repair243. Moreover, SSBs can lead to DSBs when two SSBs arise in 
close proximity, or the DNA-replication apparatus encounters an SSB244. However, DNA 
lesions can occur as a side effect of DNA metabolising processes (e.g. replication errors)245,246, 
but the highest genomic burden is induced by a variety of agents and processes that either alter 
the DNA sequence directly or cause mutations when DNA is sub-optimally repaired 242,247.  The 
most pervasive exogenous DNA damaging agent is ionising radiation (IR), which directly 
induces DSBs248. Imprecise re-joining of the broken DNA ends at DSBs causes mutations and 
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genomic aberrations, which ultimately lead to cellular dysfunction or cell death249.  In this 
respect, DSBs are the most detrimental to genomic stability. Therefore, it is important to 
understand the intricate regulation of the DNA damage response (DDR) upon DSB formation. 
To protect genomic stability, cells have evolved mechanisms that recognise and repair different 
types of DNA lesions. In this thesis, DNA damage was induced by γ-IR and Etoposide 
(topoisomerase inhibitor II), which create DSBs for inducing apoptosis, and are clinically 
useful as therapies to treat cancer. Therefore, the following section on DNA damage repair 
focuses on DSBs.  
 
1.8.2 DNA damage response 
The DDR is a large signalling transduction network that senses DNA damage and activates 
multiple cellular responses, including transcriptional changes, cell cycle transition regulation, 
recruitment of DNA repair machinery and induction of apoptosis or senescence if the DNA 
damage is irreparable250,251. Activation of a cell cycle checkpoint to regulate cell cycle transition 
is one of the multifaceted purposes of DDR252. However, the main goals of DDR are to repair 
DNA damage and facilitate DNA replication, while blocking proliferation if the damaged DNA 
is beyond repair, thereby serving a role in preventing cancer development.   
DSBs are detected by Mre11-Rad50-Nbs1 (MRN) and Ku heterodimer (Ku70/ku80) 
complexes, which subsequently recruit  proteins in the apical phosphatidylinositol 3-kinase-
like kinases (PIKKs) family. The family of PIKKs, ataxia telangectasia mutated (ATM) and 
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) are primarily activated at a DSB 
site, while ATM-and-rad-3-related (ATR) is activated by single-stranded DNA that occurs 
during the processing of DSBs or DNA replication in S phase253,254. Active PIKKs rapidly 
phosphorylate histone variant H2AX at serine 139 at sites proximal to the DSB255–257. 
Phosphorylated H2AX, which is referred to as γH2AX, serves as a platform for the recruitment 
of additional DDR factors, such as mediator of DNA damage checkpoint 1 (MDC1)258–261. 
Additional phospho-dependent recruitment of MRN and ATM by MDC1 results in 
amplification of the ATM signalling258. This leads to spread of γH2AX and MDC1 foci over a 
2Mb domain of chromatin near the DSB255. In addition, phosphorylated MDC1 recruits RING-
finger ubiquitin E3-ligases, RNF8 and RNF168, to initiate K63-linked polyubiquitination of 
H2A and H2AX. These ubiquitin chains are required for binding of BRCA1 and p53-binding 
protein 1 (53BP1), which activate the DDR262,263. 
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1.8.3 The mechanisms of DNA DSB repair 
Cells have evolved efficient mechanisms to repair DSBs through multiple pathways of 
homologous recombination (HR) and non-homologous end-joining (NHEJ) processes. DSBs 
are predominantly repaired by the canonical NHEJ pathway, which is initiated by binding of 
Ku heterodimer (Ku70/Ku80) at the DSB DNA ends264,265. Ku70/Ku80 protects the DNA ends 
against nuclease digestion, but does not impede ATM activation or signalling266,267. DNA-
bound Ku70/Ku80 recruits DNA-PKcs to form a heterotrimeric complex, DNA-PK268. This 
complex formation stabilises the DNA ends at the DSB sites, creating a synaptic complex that 
holds the two DNA termini together269. The catalytic activity of DNA-PK is activated once 
bound to DNA, phosphorylating the ligation complex, which includes DNA ligase IV, X-ray 
repair cross-complementation group 4 (XRCC4) and XRCC4 like factor/Cernunnos, for 
completion of the pathway270–273. In addition, DNA-PK activity regulates end processing by 
recruiting Artemis nuclease when resection is required for re-joining the DNA ends274. While 
NHEJ is a relatively fast and putatively error-prone pathway, which involves minor 
modification to the DNA ends, a subset of DSBs engage with the HR pathway for extensive 
processing, which uses an intact homologous template to restore the lost sequence 
information240,275,276. As a result, HR is restricted to S and G2 phase when a sister chromatid is 
available, while NHEJ is used throughout the entire cell cycle, but preferentially takes place 
during G0, G1 and early S phase277–279. HR is initiated by Mre11 endonuclease, stimulated by 
CtBP-interacting protein (CtIP) at the broken DNA ends, creating an initial single strand 
nick280,281. CtIP continues end resection, assisted by helicases and exonucleases (i.e. DNA2, 
BLM, WRN, CtIP and EXO1), promoting the formation of single strand DNA for HR282,283.  
Replication protein A (RPA) rapidly binds to the single strand DNA tail, eliminating secondary 
structures, and is subsequently replaced by RAD51 through a BRCA2-dependent process284. 
RAD51 replacement promotes invasion onto the intact homologous sequence on the sister 
chromatid, generating a D-loop necessary for Holliday junction formation285. Precise DSB 
repair ensues using the intact sister chromatid as a template, followed by resolution of the 
Holliday junctions and ligation of the DNA ends. This resolution process results in either 






1.8.4 The choice of DSB repair pathway  
The DSB repair pathway that cells select is influenced by several factors, such as cell cycle 
phase, DNA damage complexity or genomic location274.  HR requires CtIP for resection of the 
DSB end to generate single strand DNA, which is activated in a Cdk-dependent manner287.  The 
timing of Cdk activity corresponds to HR usage in S and G2 phase, which demonstrates that 
the cell cycle phase is a factor in the choice of repair pathway280,288–290. The DNA structure of 
the DSBs also affects the pathway cells use. During DNA replication in S phase, one-ended 
DSBs are generated when replication forks encounter SSBs. In this case, HR is promoted for 
DSB repair, as ligation by NHEJ requires another DNA end291. The complexity of DSBs can 
lead to resection in an ATM-dependent manner. ATM is activated throughout the cell cycle 
resulting in recruitment of 53BP1 at DSB sites292. Tight binding of 53BP1 leads to chromatin 
compaction and directly or indirectly inhibits DNA nuclease to restrict resection293. The tightly 
bound 53BP1 possibly contributes to the maintenance of the Ku70/Ku80-DNA-PKcs complex 
at the DNA ends, which promotes NHEJ. Although approximately 70% of DSBs are repaired 
by NHEJ in G2 phase, cell cycle-dependent activation of BRCA1 antagonises 53BP1 function, 
conferring 53BP1 repositioning for HR294–296.  However, the mechanism by which 53BP1 
repositioning affects a change in the chromatin environment creating a preference for HR 
progression is unclear.  
 
1.8.5 The DNA damage checkpoint at G2/M phase 
The activation of cell cycle checkpoint regulation and cell fate are strictly reliant on the phase 
of the cell cycle. Depending on the time that cells encounter DNA damage, these cells will 
either arrest in G1 or G2 phase, or delay S phase progression. These DNA damage checkpoints 
provide the time to evaluate the severity of DNA damage and initiate repair or terminal cell 
cycle exit when the damage is too extensive. After the lesion is repaired, a reversal of these 
checkpoints is required to restore the cell cycle machinery, allowing resumption of the cell 
cycle. Therefore, these checkpoints are important for maintenance of the genomic integrity of 
proliferating cells.   
The G2/M checkpoint prevents cells from initiating mitosis when encountering DNA damage 
in G2 phase, unrepaired lesions sustained from previous cell cycle phases, or when the 
replicated DNA is suboptimal297,298. The critical target of the G2/M checkpoint is the activities 
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of Cdk1 and Plk1, which are responsible for the onset of mitosis. ATM and ATR both 
contribute to the checkpoint, together with their downstream target kinases, Chk2 and Chk1, 
respectively. After the introduction of DNA DSBs, ATM and Chk2 initiate checkpoint 
activation, which is subsequently followed by ATR and Chk1 mediated cell cycle arrest. As 
part of rapid-signalling axes, ATM and ATR in turn activate both Chk2 and Chk1, which inhibit 
Cdc25299–301. Chk1-and Chk2-mediated phosphorylation of Cdc25 creates a binding site for 14-
3-3 proteins that block substrate access to the catalytic site, thereby preventing the removal of 
inhibitory phosphates on the Cdks302–305. In addition, 14-3-3 proteins stimulate the NES that 
sequesters Cdc25 in the cytoplasm, causing separation from the nuclear pools of Cdks306–310,  
and this compartmentalisation of Cdc25 impedes the activation of Cdks.  Although the p38 
MAPK family has been primarily described for non-IR types of stress induced cell cycle arrest, 
it can activate the G2/M phase checkpoint after genotoxic stress caused by IR-induced DSBs311–
313. p38 also phosphorylates Cdc25 at the same site as Chk1 and Chk2, which results in binding 
of 14-3-3 proteins. Cdc25A is mainly implicated in G1/S phase transition, but is also involved 
in mitotic entry. In addition to Chk1 and Chk2-induced 14-3-3 binding, Cdc25A is regulated 
through ubiquitin-dependent proteolysis126,314–316. At the opposite end of the bistable switch 
system, Chk1 activation has an effect on up-regulating Wee1-dependent inhibitory 
phosphorylation on Cdks, required for maintaining cell cycle arrest317. Activation of a feed 
forward loop driving Cdk1/2 and Plk1 induces mitotic entry318,319. Chk1 inhibits Plk1 activity 
by targeting the recruitment of Aurora A to Plk1/Bora complex, which prevents 
phosphorylation of Plk1 at Thr210320.  However, during checkpoint recovery, Plk1 counteracts 
Chk1 activity by targeting its co-activator, Claspin, for degradation321,322. Plk1 also inactivates 
Chk2 and 53BP1, which might contribute to inactivation of p53323,324. Checkpoint recovery in 
the absence of p53  is possible in the presence of ATR activity, but is blocked by the ATM 
spread on chromatin325.  
In unstressed conditions, expression of p53 remains low due to rapid degradation mediated by 
Mdm2 E3 ubiquitin-protein ligase326,327. In response to DNA damage, several checkpoint 
activators, including ATM, Chk1, Chk2 and p38 phosphorylate p53, thereby preventing 
recognition by Mdm2328,329. ATM phosphorylates Mdm2 directly, promoting Mdm2 for self-
ubiquitination330,331. These processes stabilise p53, which then allows it to function as a 
transcription factor. p53 up-regulates expression of p21 and directly suppresses promoters of 
several key cell cycle regulatory genes, such as cyclin B1 and Plk1, leading to cell cycle 
arrest332,333.  Depending on the level of DNA damage generated during S phase, p53-dependent 
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p21 starts to accumulate in G2 phase and continues into the subsequent G1 phase, where 
sufficiently high levels of p21 mediate arrest in G1 phase by inhibiting Cdk activity334,335.  
 
1.9 Cell fate after DNA damage 
Unresolved DNA damage is a potential threat to genomic integrity. To ensure the maintenance 
of this integrity, cells have evolved signalling pathways and mechanisms in addition to the 
DDR. Depending on the severity of DNA damage, cells can selectively engage different 
programmes, which decide the fate of the cell. This decision is not simply a choice between 
‘death’ or ‘recovery’, but a diversity of cell outcomes are possible. Thus, the focus of this 
chapter is on introducing different cell fate outcomes after DNA damage-induced cell cycle 
arrest.  
 
1.9.1 Checkpoint recovery  
Perhaps the main biological aim of a DNA damage checkpoint is to provide sufficient time to 
repair the inflicted damage before cells can eventually resume and continue the committed cell 
cycle. While the process of checkpoint recovery from G2 phase mirrors the initiation of 
unperturbed mitotic entry130, it requires a rearrangement of the cell cycle machinery, as the 
DDR inhibits the activities of pro-mitotic kinases and degrades proteins that promote mitotic 
entry336–338. In this context, Plk1 together with its activator Aurora A and Bora become essential 
for resuming the cell cycle after DNA damage-induced G2 phase arrest by activating cyclin 
B1-Cdk1130,339,340, whereas in unperturbed cells Plk1 is less important for mitotic entry. At the 
same time, recovery from this checkpoint relies on the stabilised Cdc25 isoform, Cdc25B, in 
the absence of Cdc25A, reducing the redundancy of Cdc25 phosphatases in normal mitotic 
entry340,341.                                                                      
In addition to its role in re-activating cyclin B1-Cdk1,  Plk1 regulates the silencing of DDR 
signals342,343. The checkpoint recovery in G2 phase is driven by the same mechanism that 
activates Plk1 to prevent checkpoint signalling in mitosis. During checkpoint recovery, Plk1 
phosphorylates Claspin and Wee1 for SCFβ-TrcP-mediated degradation124,342–344. While the 
degradation of Claspin inactivates its co-activator Chk1, allowing the activation of Cdc25B 
and re-accumulation of Cdc25A, the destruction of Wee1 disposes of direct Cdk 
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inhibition340,341,344. Thus, these processes converge to create feedback loops that activate cyclin 
B1-Cdk1 (See section 1.4.5). Plk1 also inactivates checkpoint signalling through inhibition of 
Chk2 by phosphorylation345,346. It has been indicated that Plk1 could facilitate inhibition of p53 
by either direct or indirect mechanisms347–350. Despite a number of findings pointing towards 
Plk1 as a key regulator that drives the transition from checkpoint arrest to recovery, there is 
little known about how Plk1 is reactivated at checkpoint recovery. Recently, a mechanism of 
Plk1 re-activation has been described, where DNA damage-dependent ATM activity across 
chromatin is counteracted by chromatin-bound Wip1 and re-activated Plk1, even in the 
presence of active ATM/ATR and DNA break sites351. Nevertheless, it should be kept in mind 
that other factors could be implicated in regulating G2 phase checkpoint recovery. Despite this, 
the role of Plk1 in activating cyclin B1-Cdk1 is insufficient to account for the entire process. 
There is emerging evidence that suggests that some phosphatases could counteract ATM/ATR 
and DNA-PK-dependent phosphorylation, bringing the balance back to the steady-state before 
DNA damage occurred. Although further supporting evidence is required, Wip1 and PP2A-
dependent dephosphorylation of γH2AX, Chk1, Chk2 and p53, are likely to represent 









1.9.2 Checkpoint adaptation  
Another mechanism that regulates the cell cycle after checkpoint arrest is related to, but 
conceptually distinct from, checkpoint recovery and termed checkpoint adaptation. Checkpoint 
adaptation was first described in S. cerevisiae where cells overrode checkpoint arrest and 
entered mitosis in the presence of unrepaired DNA damage356.  This mechanism is conserved 




in evolution, and both human and yeast cells escape checkpoint arrest in a Chk1- and Plk1-
dependent manner356–358. Degradation of Plk1 upon DNA damage insult is essential for 
checkpoint arrest, and cells expressing a constitutively active Plk1 mutant increases the fraction 
of cells proceeding to mitosis in response to DNA damage338. It has also been reported that 
irradiated G2 phase cells progress to mitosis with unresolved DNA damage, indicating 
sustained G2 phase checkpoint arrest may require a threshold of persistent DNA damage359–361. 
During checkpoint arrest, Plk1 activity continually accumulates and once it reaches a threshold 
level cells enter mitosis regardless of the presence of DNA damage or a checkpoint signal361. 
In this sense, checkpoint adaptation and recovery is possibly a related process and the duration 
of checkpoint arrest is not necessarily decided by the DNA repair status. Indeed, after 
substantial hours of delay in G2 phase, in response to DNA damage insult, cells progress into 
mitosis in a relatively synchronous manner362,363. A study based on mathematical modelling has 
demonstrated that the G2 phase checkpoint duration does not function by sensing completion 
of the DNA damage repair, but is controlled by the balance of ATM/Wip1 on chromatin351. 
Thus, checkpoint recovery or adaptation is likely to be driven by Plk1 together with other 
upstream regulators.  
Checkpoint adaptation seems unfavourable for maintaining the genomic integrity of cells. 
However, as a last resort the presence of a prolonged high level of checkpoint signalling leads 
to permanent termination of the cell cycle programme364–366. In this context, checkpoint 
adaptation provides an opportunity to repair some DNA damage without too much of a delay 
in cell cycle progression, while cell fate is decided at the next control mechanism367–372. This is 
most clearly demonstrated by cells that enter mitosis with severe DNA damage, which leads to 
apoptosis via mitotic catastrophe370–372. In cases where cells completed mitosis, the DNA-
damage signalling is attenuated, with full DDR activation only taking place when a DSB-
containing mitotic cell enters G1 phase369.  Activation of checkpoint signalling in G2 phase can 
sensitise checkpoint-abrogated cells for cell cycle arrest or delay at the next G1 phase. It has 
been reported that p21 regulates the bifurcation in Cdk2 activity at mitotic exit, which dictates 
the next cell fate. This study has demonstrated that a low level of residual Cdk2 activity 
establishes a quiescent state in cells that have completed mitosis373.  Consistent with such a 
concept, recent work has shown that activation of p53 in G2 phase is a critical step for DNA 
damage-induced quiescent daughter cells374.  This study describes that DNA damage increases 
the half-life of p53 and transmits p53 signalling into the daughter cells, inducing the de novo 
expression of p21 in these cells.  Furthermore, p21 outcompetes the mitogen signal, cyclin D1, 
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leading to the daughter cells becoming quiescent. On another note,  PP2A-B56γ-dependent 
dephosphorylation of pRb in G2 phase reduces Cdk2 activity in T98G cancer cells, which is 
required for the subsequent development of quiescence after exiting mitosis375. As ATM can 
activate PP2A by direct phosphorylation of B56γ376, ATM possibly contributes to inhibition of 
Cdk2 activity, together with p21, in checkpoint-abrogated cells to induce quiescence. Taken 
together, checkpoint adaptation in G2 phase could be essential for safeguarding genomic 
stability. Moreover, checkpoint signalling in G2 phase plays a key role in the cell fate decision 
making of checkpoint-abrogated cells.  
 
1.9.3 Terminal cell cycle exit, all the way to ‘late’ senescence 
In addition to inducing temporal cell cycle arrest, checkpoint activation can induce the terminal 
cell cycle exit programme when cells are exposed to severe DNA damage. As discussed during 
DDR, p21 suppresses Cdk activity, but is maintained at a low level, allowing time for repair of 
the damaged DNA. This remaining Cdk activity is coupled to a negative feedback loop by 
inducing p21 expression, which is required for sequestration of cyclin B1 in the nucleus and 
the transition to terminal cell cycle exit377. Also, it has been suggested that a change in the 
oscillating expression of p53 to a continual expression may be critical for p21 expression, 
driving temporal arrest to terminal cell cycle exit378. Nevertheless, cyclin B1 nuclear 
translocation marks the point-of-no-return during checkpoint arrest, as cells with nuclear cyclin 
B1 fail to enter mitosis upon checkpoint inhibition365. However, subsequent degradation of 
nuclear cyclin B1 by APC/CCdh1 is required to induce terminal cell cycle exit365. p21 is 
responsible for premature activation of APC/CCdh1 by inhibiting Emi1379,380, which reinforces 







Figure 4. p21-dependent and APC/CCdh1-mediated cell cycle termination in G2 phase 
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Cells that terminate the cell cycle eventually become senescent. Senescence is considered a 
stable and permanent state of cell cycle arrest from which cells are unable to resume the cell 
cycle, despite optimal growth conditions and mitogenic stimuli382. Although senescent cells are 
insensitive to growth stimuli, these cells are metabolically active and resistant to apoptotic cell 
death owing to an upregulation of cell survival pathways383,384. However, it remains unclear 
whether this prolonged viability is the result of the selection of cells that are resistant to 
apoptosis or is an intrinsic property of the senescence programme.  
Until now, senescence has been perceived as a static endpoint. However, several recent findings 
support the notion that senescence can be a highly dynamic and multi-step process, during 
which the properties of senescent cells evolve and diversify, as in tumourigenesis, but without 
proliferation as a driving force385–387. Progression to full senescence involves global and local 
modifications in chromatin methylation, which are suggested to be mediated by transcriptional 
downregulation of lamin B1388–390. The global induction of heterochromatin results in 
senescence-associated heterochromatin foci (SAHF) formation 391–393 , which depends on 
HIRA, ASF1 394,395, and p16 393,396.  SAHF are proposed to be enforcers of senescence by 
repressing the transcription of pro-proliferative genes  397,398. Also, senescence-related 
chromatin modification leads to enormous transcriptional changes388,399,400, including 
upregulation of genes that encode for proinflammatory secretory proteins, such as IL-6 and IL-
8401,402. These proteins are collectively termed as the senescence-associated secretory phenotype 
(SASP)401,402, and are suggested to induce local inflammation by attracting immune cells.  
The establishment of full senescence in cells grown in vitro usually takes several weeks after 
exposure to the onset of senescence, but variability exists between cells and this process can 
even take several months385. Furthermore, even after cells are fully senescent, these cells 
continue to evolve and progress to a stage referred to as ‘deep’ or ‘late’ senescence403. In late-
senescence, there is an increase in transcription of transposons and these newly synthesised 
transcripts accumulate in the cell genome385,386. This increasing transposon activity opens up 
the gene-poor heterochromatin regions, where these elements are located385. Another process 
involved in the development of late-senescent cells is the extrusion of chromatin into the 
cytoplasm, which is subsequently degraded by lysosomes and results in an overall loss of 
histones387. Thus, genomic and epigenomic re-modelling during transposon activation and the 
chromatin extrusion processes, contribute to the transcriptome diversity seen in senescent cells.  
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The dynamic nature of senescence indicates that senescence-associated cell cycle arrest may 
not necessarily be terminal. Several studies have shown that senescent cells are able to resume 
proliferation, suggesting that senescence is a biological continuum, at both the cellular intrinsic 
and extrinsic levels404–408. In line with this, recent growing evidence points towards the idea that 
cells can escape terminal cell cycle arrest after DNA-damage induced cell cycle exit in G2 
phase404,409,410. However, the mechanism of this escape and consequences on cell fidelity, remain 
elusive. A recent study suggests that oscillating p53 triggers a sharp switch between p21 and 
Cdk2, permitting cells to escape after long-term cell cycle arrest411. Furthermore, eventual 
inactivation of APC/CCdh1 has been reported in cells that escape DNA damage-induced terminal 
cell cycle exit410. The low level of p21 and inactivation of APC/CCdh1 may cause cells to be 
responsive to mitogenic stimuli.  Also, these escaped cells re-initiate S phase and progress to 
mitosis resulting in genomic heterogeneity409,410, which is often implicated in the progression 
to malignant transformation in various cancers412,413.  Thus, escaping terminal cell cycle arrest 




















  29 
2 AIMS OF THE THESIS 
 
The main aim of the work presented in this thesis is to understand the molecular mechanisms of 
cell cycle regulation in human cells. In particular, my study has focused on G2 phase regulation, 
including the long-term consequences after DNA damage, and how G2 phase is affected in a human 
genetic disorder.   
 
The specific aims addressed in this thesis are as follows:  
 
The aim of Paper I was to understand the role and mechanism of Cyclin A localisation changes in 
human cell cycle regulation. 
Paper II focused on determining the role of human long non-coding RNA gene, RMRP, in 
regulating cell cycle progression in CHH.  
Paper III  aimed to elucidate the long-term consequences of cells after DNA damage-induced cell 
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3 RESULTS AND DISCUSSION 
 
3.1 PAPER I 
Cyclin A2 localises in the cytoplasm at the S/G2 transition to activate PLK1 
Preparing entry into mitosis requires extensive cellular structural reorganisation, tightly 
coordinated by a complex network of regulatory proteins that control the timely activation of 
Cdk1415. However, the exact mechanisms that ensure spatio-temporal activation of these 
regulatory proteins during G2 phase remain elusive. We address this question through our work 
presented in Paper I.   
The main drivers of mitotic kinases, Cdk1 and Plk1, can be detected from the S/G2 phase 
transition187. Due to feedback loops, the activities of Cdk1 and Plk1 gradually increase through 
G2 phase, but the starting points of these feedback loops are difficult to define416,417. Given that 
cyclin A2 is activated before cyclin B1, and necessary for G2 phase progression85, it is 
reasonable to think that cyclin A could have a role in initiating these feedback loops. We 
therefore established an RPE cell line where eYFP is inserted in the endogenous locus of 
CCNA2 to characterise the dynamics of cyclin A2 in live cells. We revealed cytoplasmic cyclin 
A2 first appeared at the S/G2 phase transition and gradually increased throughout G2 phase. 
This indicates that the cytoplasmic appearance of cyclin A2 is coupled to this cell cycle event. 
In addition, siRNA-mediated depletion of cyclin A2 delayed S/G2 phase transition, but was 
partially rescued by induction of siRNA-resistant cytoplasmic cyclin A2. This suggests that 
cytoplasmic cyclin A2 has a role in stimulating cell cycle progression.  
We also observed cyclin A2 depletion impairs Plk1 activation, meaning that either cyclin A2 
may regulate Plk1, or the completion of S phase was impaired. We therefore monitored Plk1 
activity upon Cdk1 or Cdk2 inhibition in G2 phase to address the contribution that cyclin A2-
Cdk complexes make after the S/G2 transition. Inhibition of Cdk1 or Cdk2 decreased 
phosphorylation of Plk1 at T210, but more prominently when both Cdks were inhibited, 
indicating Cdk activity is required for Plk1 activation during G2 phase. In previous studies, 
cyclin A2-Cdk1-mediated activation of Plk1 by Bora has been described204,206. However, we 
identified that cyclin A2-Cdk2 can stimulate Aurora A-mediated activation of Plk1 by 
phosphorylating Bora. Interestingly, Bora and Plk1 both interact exclusively with cytoplasmic 
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cyclin A2 in G2 phase, indicating cyclin A2 cytoplasmic localisation is required for Plk1 
activation through Bora. This suggests Plk1 activation does not depend on specific Cdk 
activity, but it is likely that spatial regulation of cyclin A2 contributes to Cdk substrate 
specificity. This was more clearly demonstrated when we assessed the function of cyclin A2 
on Plk1 activation in cell cycle progression. Expression of active Plk1 could partially rescue 
mitotic entry after depletion of cyclin A2, indicating that Plk1 is an important target for cyclin 
A2 to promote mitosis. Taken together, cyclin A2 participates in the initial activation of Plk1 
by localising in the cytoplasm to interact with cofactor Bora during G2 phase, and thereby 
promoting mitotic entry.  
Since cyclin A2 starts to accumulate in the cytoplasm at the initiation of G2 phase, we reasoned 
that the cytoplasmic appearance of cyclin A2 could be triggered by mitotic kinase activity. 
However, we found no evidence that Cdk1 and Plk1 activity regulated cytoplasmic 
translocation of cyclin A2 at the S/G2 phase transition. This suggests cytoplasmic cyclin A2 
translocation is not a component of the feedback loops, but is an important factor for triggering 
activation of mitotic kinases. We found an indication that Cdk1 may facilitate cytoplasmic 
cyclin A2 localisation, but the presence of cytoplasmic cyclin A2 with both Cdk1 and Cdk2, 
suggests an association with Cdk1 is not solely accountable for the cytoplasmic appearance of 
cyclin A2.  Given that cyclin A2 localises in the nucleus while DNA replication occurs, and 
directly interacts with PCNA, we decided to investigate if cyclin A2 is restricted to the nucleus 
during S phase.  We observed an increased cyclin A2 association with chromatin during 
replication, and more specifically with replicating chromatin, but there was no clear mobility 
restriction of chromatin associated cyclin A2 in the nucleus between S and G2 phases. Thus, 
the decreasing association of cyclin A2 with chromatin is not responsible for the cytoplasmic 
localisation of cyclin A2 at the S/G2 phase transition.  
Activities that promote mitotic entry can be limited during DNA replication by certain 
signalling components, which resemble a low-level of DDR418,419. We therefore assessed the 
regulation of cytoplasmic cyclin A2 in response to DNA damage. Cytoplasmic cyclin A2 
rapidly translocated to the nucleus upon DNA damage and was subsequently degraded, the 
timing of which was comparable with previously described p53- and p21-mediated degradation 
of cyclin B1-eYFP. Moreover, cells that received DNA damage in G2 phase showed an 
apparent nuclear cyclin A2 loss when compared with cells that were targeted in S phase. This 
finding was consistent with the role of p21, which is active in G2 phase, but its expression is 
dampened during S phase even in the presence of DNA damage. Interestingly, knockdown of 
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p21 or p53 prevented cytoplasmic loss of cyclin A2 upon DNA damage, suggesting p21 and 
p53 can both mediate a change in the localisation of cyclin A2. Since p21 contains an NLS and 
interacts with cytoplasmic and nuclear cyclin A2 in unperturbed conditions420, we tested the 
spatial regulation of cyclin A2 by p53 and p21 without inducing external DNA damage. We 
revealed that p21 has more of an apparent role than p53 in modulating cyclin A2 localisation 
in an unperturbed cell cycle, demonstrated by the increase in cytoplasmic cyclin A2 in G2 
phase in both p21-/- and p53-/- cells, but more prominently in p21 -/- cells. This observation 
also highlights a role for p21 in regulating progression of the cell cycle in unperturbed 
conditions independently of p53.  
In conclusion, our findings underscore the importance of the spatial regulation of cyclin A2 in 
promoting mitotic entry and suggest that activation of Plk1 relies on the cytoplasmic 
localisation of cyclin A2. Although the exact mechanism for cyclin A cytoplasmic localisation 
remains elusive, our work excludes possible mechanisms that describe how cyclin A2 
localisation changes from the S/G2 transition, and adds to our limited mechanistic 











3.2 PAPER II 
The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle 
progression at G2 phase 
The founder mutation c.71A > G in mitochondrial RNA processing endoribonuclease (RMRP)  
is implicated in several diseases, including the rare autosomal recessive disorder cartilage-hair 
hypoplasia (CHH)421. While studies have highlighted a role for RMRP in cell cycle regulation 
and ribosomal assembly384,422–424, most studies have been based on experimental systems 
involving cancer and non-human cells. Interestingly, studies in yeast have indicated that RMRP 
may be regulating the levels of cyclins425. Therefore, we aimed to address the function of RMRP 
in CHH in paper II.   
Since several data indicate a direct role of RMRP in ribosomal RNA processing422–424, it is 
reasonable to assume RMRP can affect transcriptome balance. Thus, we assessed whole-
transcriptomes in CHH  patients and control individuals using the STRT RNA-seq method. For 
this study, we derived fibroblast cells from skin biopsies of CHH patients who have the c.71A 
> G RMRP mutations and healthy individuals for the control. The transcriptome data revealed 
that 35 genes were significantly upregulated and 130 genes were significantly downregulated 
in the CHH patient-derived fibroblasts. We confirmed the altered expressions of CDK2, 
IFITM1,CDKN1A and BCL2L1 genes were comparable with findings of the STRT RNA-seq 
data. Also, the Gene Ontology category and Kyoto Encyclopaedia of Genes and Genomes 
pathway analyses of downregulated genes from CHH patient-derived fibroblasts indicate 
perturbations in the cell cycle and cell cycle progression. Importantly, upregulated genes from 
CHH patient-derived fibroblasts were strongly associated with PI3K-Akt signalling, suggesting 
cell cycle regulation is impaired in CHH patient-derived fibroblasts. The PI3K-Akt signalling 
pathway has been shown to modulate growth plate chondrocyte differentiation and 
endochondral bone growth in mice, with similarities reflected in CHH phenotypes426. The 
pathway is also implicated in several malignancies, including lymphomas427, indicating the 
RMRP mutation may contribute to development of non-Hodgkin lymphomas by upregulating 
the PI3K-Akt signalling pathway in CHH patients428.  
Given that the RMRP mutation in CHH patient-derived fibroblasts represents a clear indication 
of cell cycle impairments, we assessed which specific parts of the cell cycle regulation were 
defective in CHH patient-derived fibroblasts. In line with the gene expression pattern, CHH 
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patient-derived fibroblasts had slower growth compared to control cells under the same growth 
conditions and passage numbers. Given that primary cells with growth defects are difficult to 
synchronise or create stable cell lines expressing reporters, we directly assessed cell cycle 
progression by incorporated cells with EdU during time-lapse microscopy monitoring. We 
found no difference in the proportions of EdU positive cells between the CHH patient-derived 
and control cells, indicating that the reduced proliferation in CHH patient-derived cells was 
due to a prolonged cell cycle and not the result of cell cycle termination. We unequivocally 
showed a delay in the progression from G2 phase to the next G1 phase by monitoring the 
change in DNA contents of S phase pulse-labelled cells over time. In addition, as the duration 
of mitosis in the majority of CHH patient-derived cells was similar to the control cells, we 
reasoned that the prolonged G2 phase  progression to mitosis was accountable for the reduction 
in proliferation. We noted that while positive regulators of Cdk1, such as Cdc25C, Gwl and 
Cdk2 mRNA were downregulated, the Cdk inhibitor CDKN1A mRNA was upregulated in 
CHH patient-derived cells. Thus, our findings of a delay in G2 phase in CHH patient-derived 
cells is consistent with the reduced activity and expression levels of the main players promoting 
G2 phase progression.  
In summary, our study revealed that mutations of RMRP in CHH alter the expression of 
multiple genes associated with regulating the cell cycle, which can specifically delay 
progression from G2 phase to mitosis. Thus, our study expands on our limited understanding 
of the roles of RMRP as an long non-coding RNA, specifically in CHH, and provides possible 








3.3 PAPER III 
p53-dependent polyploidisation after DNA damage in G2 phase 
Cell cycle termination is the first step towards senescence. While senescence has been 
described as a multistep process and provides protection against genomic instability385–387, the 
understanding surrounding the consequences after DNA-damage induced terminal cell cycle 
exit is limited. Previously reported cell fates after cell cycle termination reflect the data gained 
from short-term, endpoint outcome or pooled population observations366,429,430. Thus, we 
dedicated our work in paper III to delve into the long-term consequences after DNA-damage 
induced cell cycle exit in G2 phase.   
Unlike checkpoint arrest, terminal cell cycle exit in G2 phase is marked by APC/CCdh1-mediated 
degradation of all cell cycle regulatory proteins, in a p53 and p21-dependent manner365,366. Thus, 
we characterised in our system the dynamics of key G2 phase regulators, cyclin A2 and cyclin 
B1, in addition to the promoters of cell cycle exit, APC/CCdh1 and p21. The dynamics of these 
proteins were consistent with a previous report of cell cycle exit in G2 phase365, suggesting cell 
cycle exit in G2 phase had efficiently occurred after DDR activation. Using a combination of 
EdU pulse-labelling and DNA staining, we identified polyploidisation in a subset of cells 6 
days after termination of the cell cycle. We revealed that polyploidisation can spontaneously 
occur in both an immortalised cell line and primary human fibroblasts, as a consequence of 
p53-dependent cell cycle exit in G2 phase.  
In order to determine the polyploidisation process, we used RPE cells expressing a Cdk1/2 
activity sensor and monitored these cells by a combination of live-cell fluorescence microscopy 
and quantitative phase imaging (QPI). Spatial Cdk dynamics and integrated QPI intensity 
revealed that cells regain Cdk activity, while continuously increasing cell mass, several days 
after cell cycle exit in G2 phase. This suggests that cells become polyploid by re-initiating DNA 
replication with G2 phase DNA contents, upon resumption of the cell cycle several days after 
cell cycle exit in G2 phase. While p53-dependent premature activation of APC/CCdh1 mediates 
cell cycle exit365, it can also target geminin, which is required to prevent DNA replication431. 
Thus, polyploidisation paradoxically depends on p53. Interestingly, cell cycle exit from G2 
phase, also led to other cell fates, including mitotic entry after re-replication, repeated cell cycle 
exit after re-replication, and the development of senescence. This gave  rise to cells with various 
ploidies, suggesting a mechanism for creating a heterogenous population. 
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DNA damage signalling has been shown to be implicated in proliferation-arrest and 
proliferation-quiescence decision circuits78,411,432,433. However, DNA damage signalling has not 
been assessed in the context of cell cycle re-entry after long-term cell cycle termination. Thus, 
we characterised p21 and γH2AX as a DDR profile, and cyclin A2 as a Cdk1/2 activity read-
out. Fixed-cell immunofluorescence showed that regained cyclin A expression in a subset of 
polyploid G2 phase cells (EdU labelled) reflected the reactivation of Cdk1/2 several days after 
termination of the cell cycle in G2 phase. Cyclin A2 loss in polyploid cells represented repeated 
cell cycle exit after re-replication. The combination of γH2AX and cyclin A2 protein 
expressions revealed that DNA damage was continually repaired even after cell cycle exit, but 
polyploidisation processes introduced additional DNA damage to the cells. p21 expression also 
supported the ongoing DDR signalling in cell cycle terminated cells. Furthermore, our data 
suggests that re-initiation of DNA replication suppresses p21, but persistent active DNA 
damage signalling allows p21 to accumulate in polyploid cells, in turn inducing repeated cell 
cycle exit. However, the possibility that low p21 permits re-initiation of DNA replication could 
not be excluded.  
Extra centrosomes have been implicated in chromosome instability owing to the formation of 
asymmetric chromosome segregation434. Given that DNA replication involves duplication of 
centrosomes, we assessed participation of centrosome re-replication in polyploid cells. 
Immunofluorescent staining of the centrosomal component, pericentrin, revealed that a 
subpopulation of polyploid cells gained extra centrosomes during re-replication. Thus, this data 
indicates a possible new mechanism of aneuploidy development.   
In conclusion, we conferred a new mechanism of polyploidisation that is paradoxically p53-
dependent. Moreover, we shift the notion of the long-term consequence of DNA damage 
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4 METHODOLOGICAL CONSIDERATIONS 
 
Determining the dynamics of cell cycle regulatory proteins 
The cell cycle is regulated by a complex network of multiple proteins, which interact over time 
and space. Fluorescence time-lapse microscopy is one of the most suitable techniques to study 
the dynamic behaviours and localised interactions of proteins. Fluorescent transcriptional 
reporters allow immediate visualisation of the temporal gene expression of a target protein from 
a specific promoter435,436. However, endogenous promoters exhibit a low protein expression 
rate, and the transcriptional reporters generally express a low signal to noise ratio435. The 
plasmid reporter system used to express reporter constructs in cells can increase the signal to 
noise ratio, but can cause overexpression of the protein of interest, as this expression depends 
on exogenous promoters437. In the context of cell cycle regulation, the overexpression of cyclin 
A and E could alter the cell cycle and be implicated in cancer438. In this respect, a genome-
targeting approach is the preferential method to establish cell lines to study cell cycle 
regulation, despite a low signal to noise ratio. Thus, in paper I we introduced an ORF for eYFP 
in the endogenous locus of CCNA2 to construct the cyclin A2-eYFP fusion protein in RPE 
cells, to study the dynamics of cyclin A2. Even with this genome-targeted approach, we 
observed higher expression of cytoplasmic cyclin A2-eYFP (paper I). However, the temporal 
dynamics were similar between cyclin A2  and cyclin A2-eYFP and sufficient to study the 
function of cyclin A2. This demonstrates that careful consideration is required when analysing 
the functionality of a tagged endogenous protein, and the choice of method for creating 
fluorescent proteins is also of importance.  
 
Characterisation of CHH patient-derived primary fibroblasts 
Primary cells have a limited life span and generally have a slow proliferation rate when 
compared to immortalised cell lines439,440. In paper II, CHH patient-derived fibroblasts 
exhibited an even slower proliferation rate than the control fibroblasts. While flow cytometry 
can carry out high-content analysis, it requires a high number of cells. Thus, our choice of 
method for characterising CHH patient-derived fibroblast was limited, due to these cells having 
a restricted proliferation rate. In addition to limited growth, other cell characteristics can 
influence the design of an experiment. Primary cells may behave differently depending on the 
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genetic background and age of the individuals from which these cells were derived441. 
Furthermore, the characteristics of primary cells can change over time in cultured conditions442. 
Although our transcriptomic data (paper II) were reflective of the clinical manifestations of 
CHH, discrepancies were exhibited with a previously reported list of genes expressed in CHH. 
However, this study employed a different type of cell (peripheral blood lymphocytes) and 
methodology to ours. Thus, careful consideration should be given when defining the control 
group, and when selecting the method for the experiment. Nevertheless, the method that we 
selected for our analysis holds a higher sensitivity, thereby ensuring the data quality.  
 
Establishing a system to investigate the long-term consequences of DNA damage-induced cell 
cycle exit in G2 phase 
In RPE cells under unperturbed conditions, G1 phase is the longest phase of the cell cycle, 
hence the majority of cells are in G1 phase at any given time40. Therefore, induction of DNA 
damage in asynchronous cells can result in the majority of the cell population terminating the 
cell cycle from G1 phase. The hydroxyurea-induced cell synchronisation method is often used 
to arrest cells at early S phase. This method is based on reducing DNA replication, by limiting 
the dNTP pool443, but can also induce DNA damage444.  In paper III, we used hydroxyurea to 
synchronise cells to increase the number terminating the cell cycle from G2 phase upon 
inducing DNA damage, and analysed S phase progression after the cells were release from 
synchronisation to determine the effects of HU on DNA damage. Nevertheless, this 
synchronisation strategy does not generate an absolute synchronous cell population and the 
synchronisation efficiency reduces over time after synchronisation release. Moreover, DNA 
damage induction in early S phase can disrupt DNA replication, which can create additional 
factors that may influence the cell fate decision after terminal cell cycle exit in G2 phase. Thus, 
the method for discriminating cells that exit the cell cycle from G2 phase upon DNA damage 
is the most critical factor for investigating the long-term consequence of DNA damage in G2 
phase. Taking into account these factors, in paper III we introduced an EdU incorporation 
strategy to label the synchronised cells that were at late S or early G2 phase at the time of DNA 
damage induction. Using this method, we confirmed that the majority of cells contained G2 
phase DNA-contents labelled with EdU, after cells had terminated the cell cycle.  
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The first part of this thesis was to understand cell cycle regulation with a particular emphasis 
on G2 phase. G2 phase is characterised by feedback-loops that ensure a gradual build-up of 
Cdk1 and Plk1 activities, but how these feedback loops are initiated at completion of DNA 
replication remains unclear. Cyclin A is crucial for G2 progression and has been suggested to 
initiate mitotic kinase activation. However, as cyclin A-Cdk is active in S phase, why mitotic 
kinase activities are only detected at the S/G2 phase border is not known. It is therefore of 
utmost importance to determine the spatio-temporal dynamics of cyclin A2 in order to address 
our question. Our analysis of cyclin A2 in single-cells reveals cyclin A2 specifically localises 
in the cytoplasm and this localisation is likely responsible for the initiation of Plk1 activation 
(paper I). This is of significance as other reports on the initial activation of Plk1 by cyclin A2 
have focused on the levels of cyclin A2-Cdk activity, rather than the cellular localisation of 
cyclin A2. Cdk-mediated Plk1 activation in the nucleus by WAC has been reported , but it is 
unclear how this relates to our finding that nuclear cyclin A2 does not interact with Plk1, and 
the observation that restricting Plk1 to the nucleus does not result in its activation223. A 
speculative model would be that after initial activation in the cytoplasm, Plk1 activation may 
be further promoted by other mechanisms in late G2 phase. Indeed, cyclin B1-Cdk1-mediated 
Plk1 activation has been described in C. elegans and human cells204. Also, it has been reported 
that Plk1 can be re-distributed in the cell by exposure of an NLS at the KD upon initial 
activation in Drosophila224, and by SUMOylation of the PBD at Lys492 in human cells225. Thus, 
future investigations comparing the spatio-temporal activation patterns of Plk1 with 
cytoplasmic cyclin A2 are needed to test our hypothesis.  
The main mechanism of cyclin A2 cytoplasmic translocation remains elusive. However, we 
revealed that cyclin A2 association with replicating chromatin can facilitate cyclin A2 nuclear 
retention during S phase (paper I). The level of cyclin A2 dramatically rises between early S 
phase to late G2 phase. It is therefore tempting to postulate that only a limited level of cyclin 
A2 is required for chromatin association during DNA replication and this retains cyclin A2 in 
the nucleus. This raises the possibility that cyclin A2 exceeds its level at S/G2 phase transition 
allowing cyclin A2 to localise in the cytoplasm. Therefore, it would be interesting to follow up 
whether raising nuclear cyclin A2 increases cytoplasmic cyclin A2.  
 
 42 
The localisation change of regulatory proteins, such as Cdc25B, Cdc25C and cyclin B1 can in 
response to DNA damage delay progression of the cell cycle 446. The p21-dependent rapid 
nuclear translocation of cyclin B1 and its subsequent APC/CCdh1-mediated degradation in 
response to DNA damage in G2 phase has been reported365,366,429. We found that spatio-temporal 
expression of cyclin A2 after DNA damage was also similar to cyclin B1 (paper I). This raises 
the possibility that restriction of cyclin A2 in the nucleus after DNA damage may prevent Plk1 
activation in the cytoplasm. Thus, it may be worthwhile to investigate whether, after DNA 
damage, expression of cyclin A2 containing the NES can activate Plk1.  
The second part of this thesis was aimed at understanding cell cycle dysregulation and its 
relevance to disease. CHH is known to be caused by mutation of RMRP, but its implications in 
cell cycle regulation have not yet been assessed. In paper II, we found that mutation of RMRP 
in CHH patient-derived fibroblasts was implicated in causing dysregulation of cell cycle 
progression, particularly in G2 phase. We found evidence that RMRP is likely to affect major 
parts of the cell cycle network through acting on several target genes. However, the broad 
changes made to the cell cycle are coordinated by key cell cycle regulators, such as Cdks. Thus, 
it would be interesting to assess whether modulating Cdk1/2, Cdc25C and MAST-L could 
rescue G2 phase delay in CHH patient-derived fibroblasts.  
CHH is a rare genetic disorder with multiple clinical presentations including cancer. Our 
finding supports the notion of a possible impairment in the PI3K-Akt signalling pathway in 
patients with CHH (paper II). It has been reported that PI3K-Akt signalling is dysregulated in 
lymphomas427 and could promote the development of non-Hodgkin lymphomas428. Thus, direct 
assessment of the PI3K-Akt signalling pathway in CHH-patient derived cells, and correlation 
with the development of non-Hodgkin lymphomas in CHH patients, deserves further studies 
to help develop clinical interventions.  
CHH patient-derived cells have a slow growth rate with a delay in G2 phase progression. More 
interestingly p21 gene expression is upregulated in these cells. This raises the question whether 
G2 phase delay is the consequence of cell cycle arrest due to replication stress. There is also a 
possibility that CHH patient-derived cells are more prone to develop senescence, as these cells 
are difficult to cultivate. Future investigation of determining cell cycle exit and senescence in 
these cells could explain the G2 phase delay in CHH patient-derived fibroblasts. 
The last part of this thesis was to understand the long-term consequences of DNA damage in 
G2 phase (paper III). DNA damage-induced terminal cell cycle exit is perceived as the end of 
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the cell cycle programme with the only consequence being senescence. Our findings that 
multiple cell fates can arise a long time after termination of the cell cycle, by cell cycle 
resumption, raises further questions. One of the most important and fundamental questions is 
how the cell cycle resumes after terminal cell cycle exit. p21 is implicated in several cell fate 
decision circuits, therefore characterising p21 and cyclin A2 dynamics in single-cells after cell 
cycle termination would be a good starting point. Also, APC/CCdh1 prevents re-accumulation of 
cyclin A2114, and an eventual inactivation of APC/CCdh1 has been reported in cells that escape 
DNA damage-induced terminal cell cycle exit410. Correlating APC/CCdh1 activity with p21 and 
cyclin A2 activities would be the next step towards identifying an underlying mechanism. Also, 
a CRISPR-based gRNA screening approach would be useful to identify other potential 
regulators in cell cycle re-entry in an unbiased manner.  
A particular cell fate deserving future investigation is that of polyploid cells that commit to 
mitosis (paper III). The proliferation capability of polyploid cells has been indicated by these 
cells committing to mitosis, despite having inherent DNA damage. Oncogenic transformation 
is achieved through several proliferation events in cells with genetic mutations447. Therefore, it 
would be interesting to follow whether polyploid cells that enter mitosis can maintain a 
proliferation capability. The identification of the long-term proliferative capability of polyploid 
cells would be interesting to study further, to determine whether tumour formation could occur 
in vivo.   
In conclusion, the work presented in this thesis provides new insights into G2 phase regulation 
in an unperturbed cell cycle, a compromised cell cycle, and in response to DNA damage. 
Furthermore, it points to the importance of understanding cell cycle regulation in identifying 
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